These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12683651)

  • 21. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanism of action of ACE-inhibitors and angiotensin receptor antagonists in diabetic nephropathy. Recent insights].
    Martinelli L; Ceriello A
    Recenti Prog Med; 2003 Mar; 94(3):131-5. PubMed ID: 12677781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiotensin-converting enzyme inhibitors in diabetes: effect on the kidney and on blood pressure.
    Björck S; Aurell M
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S59-63. PubMed ID: 16989067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Guidelines for diagnosis and therapy of diabetic nephropathy].
    De Ferrari G;
    G Ital Nefrol; 2003; 20 Suppl 24():S96-108. PubMed ID: 14666506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
    Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of ACE inhibition on the course of nephropathy in type I diabetes mellitus.
    Meinders AE; Hes R; de Leeuw PW
    Neth J Med; 1992 Jun; 40(5-6):217-20. PubMed ID: 1436257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing antihypertensive therapy in patients with diabetic nephropathy.
    Ritz E; Rychlík I; Miltenberger-Miltenyi G
    J Hypertens Suppl; 1998 Sep; 16(7):S17-22. PubMed ID: 9855027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease.
    Ferrari P
    Nephrology (Carlton); 2007 Feb; 12(1):81-9. PubMed ID: 17295666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Underuse of ACE inhibitors and angiotensin II receptor blockers among patients with diabetic nephropathy in Taiwan.
    Yeh HL; Huang LY; Su S; Yang MC; Wang TC
    Health Policy; 2011 May; 100(2-3):196-202. PubMed ID: 21146895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetic nephropathy, percutaneous coronary interventions, and blockade of the renin-angiotensin system.
    Reinecke H; Matzkies F; Fobker M; Breithardt G; Schaefer RM
    Cardiology; 2005; 104(1):24-30. PubMed ID: 15942180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In patients with chronic diabetic nephropathy, do angiotensin-converting enzyme inhibitors (ACEI) have greater renal protective effect as compared to angiotensin receptor blockers (ARB)?
    Tucker S; Chen Y; Abell R
    J Okla State Med Assoc; 2013 Jul; 106(7):294-5. PubMed ID: 24032256
    [No Abstract]   [Full Text] [Related]  

  • 34. Diabetic nephropathy and pregnancy: the effect of ACE inhibitors prior to pregnancy on fetomaternal outcome.
    Hod M; van Dijk DJ; Karp M; Weintraub N; Rabinerson D; Bar J; Peled Y; Erman A; Boner G; Ovadia J
    Nephrol Dial Transplant; 1995 Dec; 10(12):2328-33. PubMed ID: 8808235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AT1 receptor antagonists: a challenge for ACE inhibitors in diabetic nephropathy.
    Mogyorosi A; Sonkodi S
    Diabetes Metab Res Rev; 1999; 15(1):55-8. PubMed ID: 10398547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.
    Strippoli GF; Craig M; Deeks JJ; Schena FP; Craig JC
    BMJ; 2004 Oct; 329(7470):828. PubMed ID: 15459003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Erythropoietin-depletion induced anemia in early or advanced diabetic nephropathy].
    Inomata S
    Nihon Rinsho; 2002 Aug; 60 Suppl 8():504-9. PubMed ID: 12355798
    [No Abstract]   [Full Text] [Related]  

  • 38. Should ACE inhibitors be the drugs of choice in the treatment of hypertension in diabetes mellitus? ACE inhibitors are the drugs of choice in diabetic nephropathy.
    Huddle K; Milne FJ
    S Afr Med J; 1991 Sep; 80(5):suppl 10-1; discussion suppl 12-3. PubMed ID: 1887338
    [No Abstract]   [Full Text] [Related]  

  • 39. Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy.
    Kuriyama S; Tomonari H; Abe A; Imasawa T; Hosoya T
    Nephron; 2000 Dec; 86(4):529-30. PubMed ID: 11124615
    [No Abstract]   [Full Text] [Related]  

  • 40. Renal protection in diabetes: an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    J Hypertens Suppl; 1996 Nov; 14(4):S21-5. PubMed ID: 8986939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.